Key points are not available for this paper at this time.
Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer. Myelosuppression and diarrhea were more frequent with sacituzumab govitecan. (Funded by Immunomedics; ASCENT ClinicalTrials.gov number, NCT02574455; EudraCT number, 2017-003019-21.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Aditya Bardia
Sara A. Hurvitz
Sara M. Tolaney
New England Journal of Medicine
University of California, Los Angeles
University of California, San Francisco
Massachusetts General Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Bardia et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69cac1a5c138251ffc5f8144 — DOI: https://doi.org/10.1056/nejmoa2028485
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: